M694V mutation may have a role in susceptibility to ankylosing spondylitis.
Akar
Servet
S
Birlik
Merih
M
Sari
Ismail
I
Onen
Fatos
F
Akkoc
Nurullah
N
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003078:Colchicine / Q000627:therapeutic use; D004008:Diclofenac / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D020022:Genetic Predisposition to Disease; D005944:Glucosamine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006074:Gout Suppressants / Q000627:therapeutic use; D006720:Homozygote; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D008297:Male; D009154:Mutation; D011859:Radiography; D013167:Spondylitis, Ankylosing / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000235:genetics*; D012460:Sulfasalazine / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D006074:Gout Suppressants; D004008:Diclofenac; C028423:Salazopyrine; D012460:Sulfasalazine; D005944:Glucosamine; D003078:Colchicine